Kowa Gains FDA Breakthrough Status for K-808 in PBC
NAGOYA, Japan, June 30, 2026 Kowa Company, Ltd. has achieved a significant regulatory milestone after the U.S. Food and...
AI drug discovery artificial intelligence ASCO 2026 Autoimmune Disease Bio-Pharma biologics biopharma Biotechnology Cancer Immunotherapy Cancer Research cancer therapy Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development FDA fda approval FDA clearance Gene Therapy Healthcare Innovation healthcare technology Immuno-Oncology immunology Immunotherapy Medical Device Medical Devices MedTech Monoclonal Antibody Neurodegenerative Disease Neurology Oncology oncology innovation Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 trial Precision Medicine Precision Oncology rare disease rare diseases Regenerative Medicine targeted therapy
NAGOYA, Japan, June 30, 2026 Kowa Company, Ltd. has achieved a significant regulatory milestone after the U.S. Food and...
FOSTER CITY, California, USA, June 2, 2026 Gilead Sciences has announced positive topline results from the Phase 3 IDEAL...
